Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RESEARCH TOOLSreports
Holding RANI?
Track your performance easily
RANI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.90 - $8.75
Previous Close$2.08
Volume415.48K
Average Volume (3M)1.70M
Market Cap
$119.45M
Enterprise Value$125.43M
Total Cash (Recent Filing)$30.40M
Total Debt (Recent Filing)$33.73M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Mar 19, 2025EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding57,288,682
10 Day Avg. Volume571,410
30 Day Avg. Volume1,699,630
Standard Deviation0.31
R-Squared0.00033
Alpha-0.00075
Financial Highlights & Ratios
Price to Book (P/B)41.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.66
Forecast
1Y Price Target
$12.25Price Target Upside488.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Rani Therapeutics Holdings News
PremiumCompany Announcements
Rani Therapeutics Advances in Biotherapeutics Market
PremiumMarket News
3 Penny Stocks to Watch Now, 10/15/24
PremiumStock Analysis & Ideas
Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Innovative Drug DeliveryRani Therapeutics has developed the RaniPill capsule, which is a novel, proprietary, and patented platform technology intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral administration.
Market PotentialRani’s pipeline in psoriasis, psoriatic arthritis, hypoparathyroidism, and obesity presents an opportunity to tap into a global biologics market that reached $516B in 2022 and is expected to grow to $856B by 2031.
Strategic PartnershipsThe partnership positions Rani in the GLP-1/obesity space, with the potential for significant economic benefits and the ability to conduct further development with other GLP-1 drugs.
Bears Say
Clinical TrialsNegative clinical readouts with other candidates pose a risk to the stock's performance.
Market PerformanceSlower-than-projected market uptake for key products may impact revenue expectations.
Regulatory ApprovalsFailure to achieve approvals for key pipeline projects could hinder future growth.
---
Options Prices
Currently, No data available
---
Ownership Overview
29.68% Insiders
2.75% Mutual Funds
12.38% Other Institutional Investors
52.80% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Rani Therapeutics Holdings
Desktop Users
Mobile Users
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $1.90 and its highest was $8.75 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Currently, no data Available
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is Mar 19, 2025 which is in 113 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Rani Therapeutics Holdings released its earnings results on Nov 14, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.05.
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate is -$0.26.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 33,311,543 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Rani Therapeutics Holdings reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -4.858%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
---
Rani Therapeutics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.25 (488.94% Upside)
$12.25 (488.94% Upside)
Insider Transactions
Sold Shares
Worth $10.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.48%
12-Months-Change
Fundamentals
Return on Equity
-272.52%
Trailing 12-Months
Asset Growth
-38.19%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
---
RANI Earnings Call
Q4 2024
0:00 / 0:00
---
RANI Stock 12 Month Forecast
Average Price Target
$12.25
▲(488.94% Upside)
Technical Analysis
Best Analysts Covering RANI
1 Year
1 Year Success Rate
4/18 ratings generated profit
1 Year Average Return
-28.96%
reiterated a buy rating 8 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -28.96% per trade.
---